Cancer Treatment Today

A recent phase II study fond that the BOVen rgimen was was safe and effective for the frontline treatment of TP53-mutant MCL. The 2-year progression-free survival of 72% compared favorably with previously reported outcomes with chemoimmunotherapy in TP53-mutant MCL. This regimen has also been recently published to be effective in a page 2 study for CLL and small lymphocytic lymphoma bySoumeral et al.

Based on these findings, the National Comprehensive Cancer Network (NCCN) added the BOVen regimen as a category 2A recommendation for TP53-mutated MCL.

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood (2025) 145 (5): 497–507.

Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, Carter J, Hochberg E, Barnes JA, Hamilton AM, Abramson JS, Batlevi CL, Matasar MJ, Noy A, Owens CN, Palomba ML, Kumar A, Takvorian T, Ni A, Choma M, Friedman C, Chadha P, Simkins E, Ruiters J, Sechio S, Portman D, Ramos L, Nolet N, Mahajan N, Martignetti R, Mi J, Scorsune K, Lynch J, McGree B, Hughes S, Grieve C, Roeker LE, Thompson M, Johnson PC, Roshal M, Huang J, Biondo J, Wu Q, Jacob A, Abdel-Wahab O, Zelenetz AD. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021 Dec;8(12):e879-e890. doi: 10.1016/S2352-3026(21)00307-0. PMID: 34826411; PMCID: PMC9326222.

Kumar A, Soumerai JD, Abramson JS, et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation [published online ahead of print, 2024 Oct. 22]. Blood. doi: 10.1182/blood.2024025563.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. B-Cell Lymphomas. Version 3.2024. August 26, 2024. Accessed October 30, 2024. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf